Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice

Pathology International

Volumn 64, Issue 8, 2014, Pages 388-396

  Lee, Eun Joo ^a   Kim, Ah Young ^a   Lee, Eun Mi ^a   Lee, Myeong Mi ^a   Min, Chang Woo ^a   Kang, Kyung Ku ^a   Park, Jin Kyu ^a   Hwang, Meeyul ^a   Kwon, Soon Hak ^a   Tremblay, Jacques P ^b   Jeong, Kyu Shik ^a  

^a Kyungpook National University School of Medicine   (South Korea)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Combined effect; Exon skipping; Losartan; Mdx mice; Muscle regeneration

Indexed keywords

COMPLEMENTARY DNA; DYSTROPHIN; EOSIN; HEMATOXYLIN; LOSARTAN; MESSENGER RNA PRECURSOR; MORPHOLINO OLIGONUCLEOTIDE; MYOD PROTEIN; MYOGENIC FACTOR 5; MYOGENIN; TRANSCRIPTION FACTOR PAX7; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; EXON; EXON SKIPPING; EXPERIMENTAL MUSCULOSKELETAL DISEASE; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE INJURY; MUSCLE REGENERATION; MUSCLE THICKNESS; NONHUMAN; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; QUANTITATIVE ANALYSIS; RADIOIMMUNOPRECIPITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SINGLE DRUG DOSE; SKELETAL MUSCLE; SWIMMING; THERAPY EFFECT; TREATMENT DURATION; TRICEPS SURAE MUSCLE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; PATHOLOGY; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; DYSTROPHIN; EXONS; LOSARTAN; MALE; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84906237693     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/pin.12190     Document Type: Article

References (47)

1. Hoffman EP, Knudson CM, Campbell KP etal. Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 1987; 330: 754-758.
2. Hoffman EP, Brown RH, Jr, Kunkel LM. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
3. Petrof BJ, Shrager JB, Stedman HH etal. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993; 90: 3710-3714.
4. Kumar A, Khandelwal N, Malya R etal. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J 2004; 18: 102-113.
5. Pasternak C, Wong S, Elson EL. Mechanical function of dystrophin in muscle cells. J Cell Biol 1995; 128: 355-361.
6. Meregalli M, Farini A, Parolini D etal. Stem cell therapies to treat muscular dystrophy: Progress to date. BioDrugs 2010; 24: 237-247.
7. Goudenege S, Lebel C, Huot NB etal. Myoblasts derived from normal hESCs and dystrophic hiPSCs efficiently fuse with existing muscle fibers following transplantation. Mol Ther 2012; 20: 2153-2167.
8. Baltgalvis KA, Call JA, Nikas JB etal. Effects of prednisolone on skeletal muscle contractility in mdx mice. Muscle Nerve 2009; 40: 443-454.
9. Keeling RM, Golumbek PT, Streif EM etal. Weekly oral prednisolone improves survival and strength in male mdx mice. Muscle Nerve 2007; 35: 43-48.
10. Bostick B, Yue Y, Lai Y etal. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther 2008; 19: 851-856.
11. Yoshimura M, Sakamoto M, Ikemoto M etal. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 2004; 10: 821-828.
12. Alter J, Lou F, Rabinowitz A etal. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175-177.
13. Widrick JJ, Jiang S, Choi SJ etal. An octaguanidine-morpholino oligo conjugate improves muscle function of mdx mice. Muscle Nerve 2011; 44: 563-570.
14. Wu B, Moulton HM, Iversen PL etal. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A 2008; 105: 14814-14819.
15. Wu B, Li Y, Morcos PA etal. Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009; 17: 864-871.
16. Yokota T, Nakamura A, Nagata T etal. Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther 2012; 22: 306-315.
17. Vulin A, Barthelemy I, Goyenvalle A etal. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 2012; 20: 2120-2133.
18. Cirak S, Arechavala-Gomeza V, Guglieri M etal. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: An open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595-605.
19. Malerba A, Thorogood FC, Dickson G etal. Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 2009; 20: 955-965.
20. Lu QL, Rabinowitz A, Chen YC etal. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 2005; 102: 198-203.
21. Adkin CF, Meloni PL, Fletcher S etal. Multiple exon skipping strategies to by-pass dystrophin mutations. Neuromuscul Disord 2012; 22: 297-305.
22. Kemaladewi DU, Hoogaars WM, van Heiningen SH etal. Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Med Genomics 2011; 4: 36.
23. Goyenvalle A, Wright J, Babbs A etal. Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy. Mol Ther 2012; 20: 1212-1221.
24. Martone J, De Angelis FG, Bozzoni I. U1 snRNA as an effective vector for stable expression of antisense molecules and for the inhibition of the splicing reaction. Methods Mol Biol 2012; 867: 239-257.
25. Betts CA, Wood MJ. Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. Curr Pharm Des 2013; 19: 2948-2962.
26. Moulton HM. Cell-penetrating peptides enhance systemic delivery of antisense morpholino oligomers. Methods Mol Biol 2012; 867: 407-414.
27. Amantana A, Moulton HM, Cate ML etal. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 2007; 18: 1325-1331.
28. Bernasconi P, Torchiana E, Confalonieri P etal. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995; 96: 1137-1144.
29. Bentzinger CF, Wang YX, Rudnicki MA. Building muscle: Molecular regulation of myogenesis. Cold Spring Harb Perspect Biol 2012; 4: 1-16.
30. Allen RE, Boxhorn LK. Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor. J Cell Physiol 1989; 138: 311-315.
31. Ten Broek RW, Grefte S, Von den Hoff JW. Regulatory factors and cell populations involved in skeletal muscle regeneration. J Cell Physiol 2010; 224: 7-16.
32. Cohn RD, van Erp C, Habashi JP etal. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-210.
33. Chamberlain JS. ACE inhibitor bulks up muscle. Nat Med 2007; 13: 125-126.
34. Burks TN, Andres-Mateos E, Marx R etal. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011; 3: 82ra37.
35. Park JK, Ki MR, Lee EM etal. Losartan improves adipose tissue-derived stem cell niche by inhibiting transforming growth factor-beta and fibrosis in skeletal muscle injury. Cell Transplant 2012; 21: 2407-2424.
36. Mann CJ, Honeyman K, Cheng AJ etal. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 2001; 98: 42-47.
37. Bouchentouf M, Benabdallah BF, Mills P etal. Exercise improves the success of myoblast transplantation in mdx mice. Neuromuscul Disord 2006; 16: 518-529.
38. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
39. Liadaki K, Luth ES, Kunkell LM. Co-detection of GFP and dystrophin in skeletal muscle tissue sections. Biotechniques 2007; 42: 699-700.
40. Heemskerk HA, de Winter CL, de Kimpe SJ etal. In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 2009; 11: 257-266.
41. Puri PL, Sartorelli V. Regulation of muscle regulatory factors by DNA-binding, interacting proteins, and post-transcriptional modifications. J Cell Physiol 2000; 185: 155-173.
42. Moulton HM, Fletcher S, Neuman BW etal. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 2007; 35: 826-828.
43. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 2010; 1798: 2296-2303.
44. Brussee V, Tardif F, Tremblay JP. Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. Neuromuscul Disord 1997; 7: 487-492.
45. Lynch GS, Hayes A, Lam MH etal. The effects of endurance exercise on dystrophic mdx mice. II. Contractile properties of skinned muscle fibres. Proc Biol Sci 1993; 253: 27-33.
46. Hayes A, Williams DA. Contractile properties of clenbuterol-treated mdx muscle are enhanced by low-intensity swimming. J Appl Physiol 1997; 82: 435-439.
47. van Putten M, Hulsker M, Nadarajah VD etal. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE 2012; 7: e31937.